- Home
- VRTX vs TD Comparison
VRTX vs TD Comparison
Compare VRTX & TD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- TD
- Stock Information
- Founded
- VRTX 1989
- TD 1855
- Country
- VRTX United States
- TD Canada
- Employees
- VRTX N/A
- TD N/A
- Industry
- VRTX EDP Services
- TD
- Sector
- VRTX Technology
- TD
- Exchange
- VRTX Nasdaq
- TD Nasdaq
- Market Cap
- VRTX 104.8B
- TD 94.8B
- IPO Year
- VRTX 1991
- TD N/A
- Fundamental
- Price
- VRTX $422.00
- TD $57.50
- Analyst Decision
- VRTX Buy
- TD Buy
- Analyst Count
- VRTX 30
- TD 2
- Target Price
- VRTX $503.92
- TD $83.50
- AVG Volume (30 Days)
- VRTX 2.1M
- TD 2.7M
- Earning Date
- VRTX 02-03-2025
- TD 02-27-2025
- Dividend Yield
- VRTX N/A
- TD 5.20%
- EPS Growth
- VRTX N/A
- TD N/A
- EPS
- VRTX N/A
- TD 3.39
- Revenue
- VRTX $10,625,800,000.00
- TD $38,208,826,702.00
- Revenue This Year
- VRTX $12.56
- TD N/A
- Revenue Next Year
- VRTX $8.34
- TD $4.69
- P/E Ratio
- VRTX N/A
- TD $16.92
- Revenue Growth
- VRTX 10.06
- TD 7.78
- 52 Week Low
- VRTX $377.85
- TD $51.25
- 52 Week High
- VRTX $519.88
- TD $64.91
- Technical
- Relative Strength Index (RSI)
- VRTX 48.34
- TD 74.06
- Support Level
- VRTX $397.25
- TD $53.03
- Resistance Level
- VRTX $425.49
- TD $54.89
- Average True Range (ATR)
- VRTX 8.24
- TD 0.79
- MACD
- VRTX 3.71
- TD 0.46
- Stochastic Oscillator
- VRTX 79.84
- TD 92.60
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About TD Toronto Dominion Bank (The)
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, US retail banking, and wholesale banking. The bank's US operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.